Silver Spring, Maryland—(ENEWSPF)—February 15, 2018
By: Angela Stark
The U.S. Food and Drug Administration today approved Erleada (apalutamide) for the treatment of patients with prostate cancer that has not spread (non-metastatic), but that continues to grow despite treatment with hormone therapy (castration-resistant). This is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer.
“The FDA evaluates a variety of methods that measure a drug’s effect, called endpoints, in the approval of…
